In a Bayesian phase 3 RCT of 157 adults with endotoxic septic shock, polymyxin B haemoadsorption plus standard care vs standard care had 28-day mortality of 39% vs 45% (posterior probability of benefit 95.3%); serious adverse events were 30% vs 22%.
RCTn = 157
Neyra et al. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial